Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; a new simplified technique in isolated hepatic perfusion

Annals of Surgical Oncology

Volumn 15, Issue 5, 2008, Pages 1367-1374

  Verhoef, Cornelis ^a   De Wilt, Johannes H W ^a   Brunstein, Flavia ^a   Marinelli, Andreas W K S ^a   Van Etten, Boudewijn ^a   Vermaas, Maarten ^a   Guetens, Gunther ^b   De Boeck, Gert ^b   De Bruijn, Ernst A ^b   Eggermont, Alexander M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Hypoxic; Isolated hepatic perfusion; Melphalan; Metastasis; Retrograde outflow

Indexed keywords

ALBUMIN; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; MELPHALAN; OXALIPLATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING DISORDER; CANCER SURVIVAL; CAVA VEIN OBSTRUCTION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GASTROINTESTINAL TOXICITY; HEPATIC ARTERY; HUMAN; HYPOXIA; LEUKOPENIA; LIVER METASTASIS; LIVER PERFUSION; LIVER TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OPERATION DURATION; OXYGENATION; PORTAL VEIN; SIDE EFFECT; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; EYE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MELPHALAN; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PORTAL VEIN; SARCOMA; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 41549166543     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9714-z     Document Type: Article

References (37)

1. Sasson AR, Sigurdson ER. Surgical treatment of liver metastases. Semin Oncol J 2002; 29:107-18
2. Malafosse R, Penna C, Sa CA, et al. Surgical management of hepatic metastases from colorectal malignancies. Ann Oncol 2001; 12:887-94
3. Wagner JS, Adson MA, Van Heerden JA, et al. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg 1984; 199:502-8
4. Verhoef C, de Wilt JHW, Verheul HMW. Angiogenesis inhibitors: perspectives in medical, surgical and radiation oncology. Curr Pharm Des 2006; 12:2623-30
5. Salmon JS, Lockhart AC, Berlin J. Anti-angiogenic treatment of gastrointestinal malignancies. Cancer Invest 2005; 23:712-26
6. Bendell J. Optimum chemotherapy for metastatic colorectal cancer. Lancet 2006; 368:2039-40
7. Daly JM, Kemeny N, Sigurdson E, et al. Regional infusion for colorectal hepatic metastases. A randomized trial comparing the hepatic artery with the portal vein. Arch Surg 1987; 122:1273-7
8. Kemeny N, Kata F. Hepatic-arterial chemotherapy. Lancet Oncol 2001; 2:418-28
9. Sterchi JM. Hepatic artery infusion for metastatic neoplastic disease. Surg Gynaecol Obstet 1985; 160:477-89
10. Alexander HRJ, Bartlett DL, Libutti SK. Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver. Oncologist 2000; 5:416-24
11. Bartlett DL, Libutti SK, Figg WD, et al. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 2001; 129:176-87
12. Marinelli A, de Brauw LM, Beerman H, et al. Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver. Jpn J Clin Oncol 1996; 26:341-50
13. Vahrmeijer AL, van Dierendonck JH, Keizer HJ, et al. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. Br J Cancer 2000; 82:1539-46
14. de Vries MR, Borel Rinkes IH, van der Velde CJ, et al. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. Recent Results Cancer Res 1998; 147:107-19
15. Rothbarth J, Pijl ME, Vahrmeijer AL, et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver. Br J Surg 2003; 90:1391-7
16. Alexander HR Jr, Libutti SK, Pingpank JF, et al. Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann Surg Oncol 2005; 12:138-44
17. van Etten B, Brunstein F, van IJken MG, et al. Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: a phase I and II study. Ann Surg Oncol 2004; 11:598-605
18. van IJken MG, de Bruijn EA, de Boeck G, et al. Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs. Ann Surg 1998; 228:763-70
19. WHO Handbook for Reporting Results of Cancer Treatment. 600 Geneva, World Health Organization. 1979
20. Tjaden UR, de Bruijn EA. Chromatographic analysis of anticancer drugs. J Chromatogr 1990; 531:235-94
21. Rothbarth J, Woutersen RA, Sparidans RW, et al. Melphalan antitumor efficacy and hepatotoxicity: the effect of variable infusion duration in the hepatic artery. J Pharmacol Exp Ther 2003; 305:1098-103
22. Teicher BA, Lazo JS, Sartorelli AC. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 1981; 41:73-81
23. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989; 49:6449-65
24. Rothbarth J, Tollenaar RA, Schellens JH, et al. Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives. Eur J Cancer 2004; 40:1812-24
25. Rothbarth J, Sparidans RW, Beijnen JH, et al. Reduced liver uptake of arterially infused melphalan during retrograde rat liver perfusion with unaffected liver tumor uptake. J Pharmacol Exp Ther 2002; 303:736-40
26. Grover A, Alexander HR Jr. The past decade of experience with isolated hepatic perfusion. Oncologist 2004; 9:653-64
27. de Wilt JH, van Etten B, Verhoef C, et al. Isolated hepatic perfusion: experimental evidence and clinical utility. Surg Clin North Am 2004; 84:627-41
28. Brunstein F, Eggermont AMM, aan de Wiel-Ambagtsheer G, et al. Synergistic antitumor effects of histamine plus melphalan in isolated hepatic perfusion for liver metastases. Ann Surg Oncol 2007; 14:795-801
29. Hoving S, Brunstein F, aan de Wiel-Ambagtsheer G, et al. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats. Cancer Res 2005; 65:4300-8
30. Rajpal S, Moore R, Karakousis CP. Survival in metastatic ocular melanoma. Cancer 1983; 52:334-6
31. Seregard S, Kock E. Prognostic indicators following enucleation for posterior uveal melanoma. A multivariate analysis of long-term survival with minimized loss to follow-up. Acta Ophthalmol Scand 1995; 73:340-4
32. Gragoudas ES, Egan KM, Seddon JM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology 1991; 98:383-9; discussion 390
33. Kath R, Hayungs J, Bornfeld N, et al. Prognosis and treatment of disseminated uveal melanoma. Cancer 1993; 72:2219-23
34. Albert DM, Niffenegger AS, Willson JK. Treatment of metastatic uveal melanoma: review and recommendations. Surv Ophthalmol 1992:429-38
35. Noter SL, Rothbarth J, Pijl ME, et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Melanoma Res 2004; 14:67-72
36. Feldman ED, Pingpank JF, Alexander HR Jr. Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol 2004; 11:290-7
37. Alexander HR Jr, Libutti SK, Pingpank JF, et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2003; 9:6343-9